Chimeric Therapeutics To Attend BIO International Convention
June 05, 2023 07:30 ET
|
Chimeric Therapeutics
SYDNEY, Australia and NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX: CHM) (“Chimeric Therapeutics”, “Chimeric” or the “Company”), a clinical-stage cell therapy company and...
Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial
June 04, 2023 20:57 ET
|
Chimeric Therapeutics
New CHM 1101 (CLXT CAR T) multi-center clinical trial activated at Sarah Cannon Research Institute (SCRI) in Austin, TexasEnrolment now open to patients with recurrent and/or progressive glioblastoma...